Shilpa Medicare Ltd
SHILPAMED
Company Profile
Business description
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company's product range includes over 44 oncology and non-oncology APIs. It uses nano and micro technology in its drug identification and formulation. The operating segments of the company are Pharmaceutical products and services, which is the key revenue-generating segment; and Power sales. Geographically, the group derives revenue from India and Outside India, of which prime revenue is generated from India.
Contact
Hyderabad Road
Number 12-6-214/A-1
Shilpa House
RaichurKA584135
INDT: +91 8532238704
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
931
Stocks News & Analysis
stocks
We take a different view to market on ASX bloodbath
Sales growth at CSL was lower than expected but streamlining the business has its perks.
stocks
BHP earnings weaker with lower iron ore prices more than offsetting higher copper volumes
Results were softer than expected.
stocks
Moated ASX player makes moves to support growth in China
a2Milk announced an acquisition and a divestiture as it aims to take a bigger slice of China’s baby formula market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,197.40 | 23.60 | 0.26% |
| CAC 40 | 7,979.08 | 95.03 | 1.21% |
| DAX 40 | 24,423.07 | 108.30 | 0.45% |
| Dow JONES (US) | 44,922.27 | 10.45 | 0.02% |
| FTSE 100 | 9,189.22 | 31.48 | 0.34% |
| HKSE | 25,016.62 | 106.28 | -0.42% |
| NASDAQ | 21,314.95 | 314.82 | -1.46% |
| Nikkei 225 | 42,871.06 | 675.23 | -1.55% |
| NZX 50 Index | 13,072.25 | 143.57 | 1.11% |
| S&P 500 | 6,411.37 | 37.78 | -0.59% |
| S&P/ASX 200 | 8,934.20 | 38.00 | 0.43% |
| SSE Composite Index | 3,731.58 | 4.29 | 0.12% |